rct
2017
Phase I clinical trial of safety of L-serine for ALS patients
Levine TD, Miller RG, Bradley WG
Published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 18 (1-2), pp. 107-111
Key Findings
L-serine up to 30 g/day was safe and well tolerated in ALS, with a non-significant trend toward slower functional decline.
Conclusions
Safety established; efficacy unproven.
Limitations
Phase I, no efficacy power.
Supplements Studied
L-Serine
Amino Acid
L-serine up to 30 g/day was safe in ALS, with only a non-significant trend toward slower functional decline.
Outcomes Measured
L-serine was safe in ALS with a non-significant trend toward slower functional decline.
Study Details
Year:2017
Sample Size:20
Duration:26 weeks
Quality Score:5/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.